Eftyhia Vardas

Summary

Affiliation: University of Cape Town
Country: South Africa

Publications

  1. ncbi request reprint Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood-borne viruses
    E Vardas
    Department of Community Health, University of Witwatersrand, Johannesburg, South Africa
    J Hosp Infect 50:6-12. 2002
  2. ncbi request reprint Preparing for phase II/III HIV vaccine trials in Africa
    Eftyhia Vardas
    Perinatal HIV Research Unit, University of the Witwatersrand, PO Box 114, Diepkloof 1864, Johannesburg, South Africa
    Microbes Infect 7:1436-44. 2005
  3. ncbi request reprint Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study
    Maria A Papathanasopoulos
    HIV Pathogenesis Research Laboratory, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, Parktown, Johannesburg, South Africa
    AIDS Res Hum Retroviruses 26:705-9. 2010
  4. doi request reprint Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects
    Eftyhia Vardas
    Lancet Laboratories, Richmond, Johannesburg, South Africa
    Vaccine 30:4046-54. 2012
  5. doi request reprint A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus
    Eftyhia Vardas
    Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
    AIDS Res Hum Retroviruses 26:933-42. 2010
  6. doi request reprint Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population
    Maria Paximadis
    Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services and the University of the Witwatersrand, Johannesburg, South Africa
    Hum Immunol 73:80-92. 2012
  7. pmc External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents
    Eftyhia Vardas
    Division of Medical Virology, University of Stellenbosch, South Africa and Lancet Laboratories, Johannesburg, South Africa
    J Infect Dis 203:58-65. 2011
  8. ncbi request reprint HIV testing using dried blood spots
    Rogerio Phili
    Special Pathogens Unit, National Institute for Virology, Johannesburg, South Africa
    Trop Doct 32:30. 2002
  9. ncbi request reprint Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa
    Graham Lindegger
    HIV AIDS Vaccines Ethics Group, School of Psychology, University of KwaZulu Natal, Pietermaritzburg, Private Bag X01, Scottsville 3209, South Africa
    J Acquir Immune Defic Syndr 43:560-6. 2006
  10. pmc Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example
    Kyeen M Andersson
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510, USA
    J Acquir Immune Defic Syndr 46:78-90. 2007

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood-borne viruses
    E Vardas
    Department of Community Health, University of Witwatersrand, Johannesburg, South Africa
    J Hosp Infect 50:6-12. 2002
    ..HCV recommendations are based on appropriate education of HCWs about this infection and its prevention and a standardized post-exposure testing protocol...
  2. ncbi request reprint Preparing for phase II/III HIV vaccine trials in Africa
    Eftyhia Vardas
    Perinatal HIV Research Unit, University of the Witwatersrand, PO Box 114, Diepkloof 1864, Johannesburg, South Africa
    Microbes Infect 7:1436-44. 2005
    ..Plans and ongoing work in the context of the AIDS Vaccine Integrated Project and some preliminary data are presented...
  3. ncbi request reprint Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study
    Maria A Papathanasopoulos
    HIV Pathogenesis Research Laboratory, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, Parktown, Johannesburg, South Africa
    AIDS Res Hum Retroviruses 26:705-9. 2010
    ..The predominance of HIV-1 subtype C in South African populations is therefore confirmed in the AVIP cohort finalized for testing preventive or therapeutic vaccines against HIV-1 infection...
  4. doi request reprint Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects
    Eftyhia Vardas
    Lancet Laboratories, Richmond, Johannesburg, South Africa
    Vaccine 30:4046-54. 2012
    ..We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate...
  5. doi request reprint A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus
    Eftyhia Vardas
    Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
    AIDS Res Hum Retroviruses 26:933-42. 2010
    ..Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV...
  6. doi request reprint Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population
    Maria Paximadis
    Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services and the University of the Witwatersrand, Johannesburg, South Africa
    Hum Immunol 73:80-92. 2012
    ..However, vaccine coverage estimation came close to 100% in both population groups, with inclusion of only four Supertype families (A1, A2, B7, B58)...
  7. pmc External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents
    Eftyhia Vardas
    Division of Medical Virology, University of Stellenbosch, South Africa and Lancet Laboratories, Johannesburg, South Africa
    J Infect Dis 203:58-65. 2011
    ..We examined the baseline prevalence of penile, scrotal, and perineal/perianal human papillomavirus (HPV) in heterosexual men (HM). We also evaluated baseline characteristics of HM to assess factors associated with prevalent HPV detection...
  8. ncbi request reprint HIV testing using dried blood spots
    Rogerio Phili
    Special Pathogens Unit, National Institute for Virology, Johannesburg, South Africa
    Trop Doct 32:30. 2002
  9. ncbi request reprint Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa
    Graham Lindegger
    HIV AIDS Vaccines Ethics Group, School of Psychology, University of KwaZulu Natal, Pietermaritzburg, Private Bag X01, Scottsville 3209, South Africa
    J Acquir Immune Defic Syndr 43:560-6. 2006
    ..This study designed and compared 4 measures of understanding for potential participants being prepared for enrollment in South African HIV vaccine trials, using detailed operational scoring criteria...
  10. pmc Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example
    Kyeen M Andersson
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510, USA
    J Acquir Immune Defic Syndr 46:78-90. 2007
    ..Even modestly effective HIV vaccines can confer enormous benefits in terms of HIV infections averted and decreased HIV prevalence. However, programs to reduce risk behavior may be important components of successful vaccination campaigns...
  11. ncbi request reprint Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans
    Stefano Butto
    Laboratory of Virology, Istituto Superiore di Sanita, University of Rome La Sapienza, Rome, Italy
    J Infect Dis 188:1171-80. 2003
    ..These data indicate an effective cross-recognition of a B-clade laboratory strain-derived Tat protein vaccine by individuals infected with different local viruses, owing to the high similarity of Tat epitopes...
  12. ncbi request reprint Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity
    Barry S Peters
    Kings College London, UK
    Vaccine 25:2120-7. 2007
    ..Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA)...
  13. ncbi request reprint HIV-1 Tat-based vaccines: from basic science to clinical trials
    Emanuele Fanales-Belasio
    Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    DNA Cell Biol 21:599-610. 2002
    ..Based on these results and on data of Tat conservation and immune cross-recognition in field isolates from different clades, phase I clinical trials are being initiated in Italy for both preventive and therapeutic vaccination...
  14. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
    ..Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples...
  15. pmc Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States
    Edward Nwanegbo
    Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15219, USA
    Clin Diagn Lab Immunol 11:351-7. 2004
    ..Because of the ability of adenoviruses to elicit systemic and mucosal immune responses, Ad35 with its low NAb prevalence appears to be an attractive candidate vector for gene therapy applications...